ClinicalTrials.gg
CompletedNCT00287716Updated May 22, 2017Results posted

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-05-22.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
6th of 21
435 · median 89
Started
2006
with 1 other
Phase 3
6 of 21
1 open now
Registered
2nd of 21
by date
Lead sponsor
5 of 21
Genentech, Inc.

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 6th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 3, and was the 2nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone 1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.

Read the detailed description

This is a Phase 3, randomized, double blind, placebo-controlled, three-arm, safety and efficacy study of pirfenidone in patients with idiopathic pulmonary fibrosis. Approximately 400 patients at approximately 70 centers will be randomly assigned (2:2:1) to receive either 2403 milligrams (mg) of pirfenidone, placebo equivalent, or 1197 mg of pirfenidone administered in divided doses three times per day (TID) with food. Patients will be randomized by geographic region.

Patients will receive blinded study treatment from the time of randomization until the last patient randomized has been treated for 72 weeks. A Data Monitoring Committee (DMC) will periodically review safety and efficacy data to ensure patient safety.

After week 72, patients who meet the Progression of Disease (POD) definition, which is a ≥ 10% absolute decrease in percent predicted FVC or a ≥ 15% absolute decrease in percent predicted carbon monoxide diffusing capacity (DLco), will be eligible to receive permitted IPF therapies in addition to their blinded study drug. Permitted IPF therapies include corticosteroids, azathioprine, cyclophosphamide and N-acetyl-cysteine (with restrictions).

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic
  • Pulmonary
  • Fibrosis
  • Lung
  • Pirfenidone
  • InterMune
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion criteria:

  • diagnosis of idiopathic pulmonary fibrosis
  • 40 to 80 years of age
  • Forced Vital Capacity greater than or equal to 50% predicted value
  • Carbon monoxide diffusing capacity greater than or equal to 35% predicted value
  • either Forced Vital Capacity or Carbon monoxide diffusing capacity less than or equal to 90% predicted value
  • no improvement in past year
  • able to walk 150 meters in 6 minutes and maintain saturation greater than or equal to 83% while on no more than 6 liters per minute (L/min) supplemental oxygen

Primary Exclusion criteria:

  • unable to undergo pulmonary function testing
  • evidence of significant obstructive lung disease or airway hyper-responsiveness
  • in opinion of investigator patient is expected to need and be eligible for a lung transplant within 72 weeks after randomization
  • active infection
  • liver disease
  • cancer or other medical condition likely to result in death within 2 years
  • diabetes
  • pregnancy or lactation
  • substance abuse
  • personal or family history of long (Q wave,T wave) syndrome
  • other IPF treatment
  • unable to take study medication
  • withdrawal from other IPF trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
435 participants (actual)

Study arms

  • Active comparator
    2403 mg/day pirfenidone

    Active arm 1, 2403 mg/day pirfenidone dose group.

    Drug: Pirfenidone

  • Active comparator
    1197 mg/day pirfenidone

    Active arm 2, 1197 mg/day pirfenidone.

    Drug: Pirfenidone

  • Placebo comparator
    placebo

    Placebo equivalent.

    Drug: Placebo

Interventions

  • 1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

  • DrugPlacebo

    Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Percent Predicted Forced Vital Capacity (FVC)

    Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72.

    Time frame: From baseline up to 72 weeks

Secondary outcomes

  1. Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity (FVC)

    Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experienced a Categorical Change in Percent Predicted Forced Vital Capacity.

    Time frame: baseline up to 72 weeks

  2. Progression-free Survival (PFS)

    Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.

    Time frame: Baseline to Week 72

  3. Change in Six-Minute Walk Test (6MWT)Distance

    The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test as measured in meters (m).

    Time frame: Baseline to Week 72

  4. Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test

    The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.

    Time frame: Baseline to Week 72

  5. Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs

    Time frame: Baseline to Week 72

  6. Change in Dyspnea Score

    The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5), with 0 = not at all breathless, 4= severely breathless and 5 = Maximally or unable to do because of breathlessness.

    Time frame: Baseline to Week 72

  7. Worsening of Idiopathic Pulmonary Fibrosis (IPF)

    Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.

    Time frame: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.

07

Results

Posted Jun 13, 2011

Participant flow

Participant flow — Overall Study
MilestonePirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Started17487174
Completed13670143
Not completed381731

Outcome measures

SecondaryCategorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity (FVC)

Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experienced a Categorical Change in Percent Predicted Forced Vital Capacity.

Time frame:
baseline up to 72 weeks
Reported as:
Number · Patients
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity (FVC)
PatientsPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Severe decline of >=20%, death, or lung transplant14927
Moderate decline of <20% but >=10%211433
Mild decline of <10% but >=0%975190
Mild improvement of >0% but <10%401224
Moderate improvement of >=10%210
SecondaryProgression-free Survival (PFS)

Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.

Time frame:
Baseline to Week 72
Reported as:
Number · Number of Patients with Progression
Progression-free Survival (PFS)
Number of Patients with ProgressionPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Death or Disease Progression452862
Decline in Percent Predicted FVC >=10%281639
Decline in Percent Predicted DLco >=15%959
Death Before Disease Progression8714
Statistical analysis
  • Pirfenidone 2403 mg/Day vs Placebo · Log Rank · p = 0.023 · Hazard ratio (hr): 0.64 · 95% CI 0.44 to 0.95
SecondaryChange in Six-Minute Walk Test (6MWT)Distance

The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test as measured in meters (m).

Time frame:
Baseline to Week 72
Reported as:
Mean · Change in Distance Walked in Meters
Change in Six-Minute Walk Test (6MWT)Distance
Change in Distance Walked in MetersPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Change in Six-Minute Walk Test (6MWT)Distance-60 ± 121-76 ± 132-77 ± 135
SecondaryChange in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test

The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.

Time frame:
Baseline to Week 72
Reported as:
Mean · Change,Worst Oxygen Saturation (Percent)
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test
Change,Worst Oxygen Saturation (Percent)Pirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test-2 ± 4-1 ± 5-2 ± 5
SecondaryChange in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs
Time frame:
Baseline to Week 72
Reported as:
Mean · Change in Percent Predicted DLco
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs
Change in Percent Predicted DLcoPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs-8 ± 10-9 ± 11-10 ± 12
PrimaryAbsolute Change in Percent Predicted Forced Vital Capacity (FVC)

Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72.

Time frame:
From baseline up to 72 weeks
Reported as:
Mean · Change in Percent Predicted FVC
Absolute Change in Percent Predicted Forced Vital Capacity (FVC)
Change in Percent Predicted FVCPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Absolute Change in Percent Predicted Forced Vital Capacity (FVC)-8.0 ± 16.47-10.0 ± 16.68-12.4 ± 18.45
SecondaryChange in Dyspnea Score

The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5), with 0 = not at all breathless, 4= severely breathless and 5 = Maximally or unable to do because of breathlessness.

Time frame:
Baseline to Week 72
Reported as:
Mean · Change in Dyspnea Score
Change in Dyspnea Score
Change in Dyspnea ScorePirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Change in Dyspnea Score12 ± 2414 ± 2515 ± 26
SecondaryWorsening of Idiopathic Pulmonary Fibrosis (IPF)

Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.

Time frame:
Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.
Reported as:
Number · Number of Patients Who Worsened
Worsening of Idiopathic Pulmonary Fibrosis (IPF)
Number of Patients Who WorsenedPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Worsening of Idiopathic Pulmonary Fibrosis (IPF)261030
Statistical analysis
  • Pirfenidone 2403 mg/Day vs Placebo · Log Rank · p = 0.515 · Hazard ratio (hr): 0.84 · 95% CI 0.50 to 1.42

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone 2403 mg/Day—60/174 (34.5%)171/174 (98.3%)
Pirfenidone 1197 mg/Day—28/87 (32.2%)86/87 (98.9%)
Placebo—58/174 (33.3%)169/174 (97.1%)
Most frequent serious events
Showing 10 of 157
Most frequent serious events
EventPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
Idiopathic Pulmonary FibrosisRespiratory, thoracic and mediastinal disorders13/1745/8714/174
Atrial FibrillationCardiac disorders1/1743/871/174
Coronary Artery DiseaseCardiac disorders0/1743/872/174
Chest PainGeneral disorders5/1743/873/174
PneumoniaInfections and infestations4/1743/876/174
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/1743/871/174
Respiratory FailureRespiratory, thoracic and mediastinal disorders2/1743/872/174
Angina PectorisCardiac disorders2/1742/871/174
Myocardial InfarctionCardiac disorders0/1742/874/174
BronchitisInfections and infestations2/1742/872/174
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlacebo
NauseaGastrointestinal disorders60/17422/8732/174
RashSkin and subcutaneous tissue disorders53/17415/8718/174
DizzinessNervous system disorders33/17414/8717/174
DyspepsiaGastrointestinal disorders30/17412/8716/174
InsomniaPsychiatric disorders22/17413/8712/174
Photosensitivity reactionSkin and subcutaneous tissue disorders25/1746/872/174
VomitingGastrointestinal disorders24/17411/877/174
ArthralgiaMusculoskeletal and connective tissue disorders20/1749/8713/174
AstheniaGastrointestinal disorders15/17410/875/174
AnorexiaMetabolism and nutrition disorders19/1749/877/174

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlaceboTotal
<=18 years0000
Between 18 and 65 years752873176
>=65 years9959101259
Age, Continuous
Age, Continuous(years)Pirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlaceboTotal
Mean65.7 ± 8.1568 ± 7.6366.3 ± 7.5366.4 ± 7.83
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlaceboTotal
Female562246124
Male11865128311
Region of Enrollment
Region of Enrollment(participants)Pirfenidone 2403 mg/DayPirfenidone 1197 mg/DayPlaceboTotal
United States11458114286
Europe34183890
Mexico2013
Canada2181847
Australia3339
08

Study locations

1 site
  • InterMune, Inc.
    Brisbane, California 94005, United States
09

References and documents

Publications

  • Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022 Aug;77(8):829-833. doi: 10.1136/thoraxjnl-2021-218577. Epub 2022 Jun 10. PubMed 35688625 ↗
  • Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, Atwood M, Kirchgaessler KU, Maher TM. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Jul 1;204(1):74-81. doi: 10.1164/rccm.202003-0669OC. PubMed 33434107 ↗
  • Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW. Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Oct;36(10):2910-2926. doi: 10.1007/s12325-019-01052-y. Epub 2019 Aug 10. Erratum In: Adv Ther. 2019 Oct;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6. PubMed 31401786 ↗
  • Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24. PubMed 31153107 ↗
  • Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. Chest. 2019 Oct;156(4):706-714. doi: 10.1016/j.chest.2019.04.015. Epub 2019 Apr 29. PubMed 31047956 ↗
  • Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22. PubMed 30472023 ↗
  • Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018. PubMed 30116539 ↗
  • Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med. 2018 Aug;6(8):615-626. doi: 10.1016/S2213-2600(18)30185-1. Epub 2018 Jun 29. PubMed 30072107 ↗
  • Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC. PubMed 28388260 ↗
  • Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax. 2017 Feb;72(2):148-153. doi: 10.1136/thoraxjnl-2016-208819. Epub 2016 Oct 5. PubMed 27708114 ↗
  • Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11. PubMed 26968970 ↗
  • Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016. PubMed 26835133 ↗
  • Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. PubMed 21571362 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2006 to primary completion in Nov 2008, 27 months.

Results were first posted in Jun 2011, 2 years 7 months after primary completion. A results delay was requested in Aug 2009.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2006
First posted
Feb 7, 2006
StartActual
Jul 14, 2006
Primary completionActual
Nov 10, 2008
CompletionActual
Nov 10, 2008
Results delay requested
Aug 25, 2009
Results first posted
Jun 13, 2011
Last update
May 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00287716
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 7, 2006
Start date
Jul 14, 2006
Primary completion
Nov 10, 2008
Completion
Nov 10, 2008
Results posted
Jun 13, 2011
Last update
May 22, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion